头孢哌酮-舒巴坦治疗下呼吸道感染73例

Cefoperazone/sulbactam in treating lower respiratory tract infections in 73 patients

目的：观察头孢哌酮-舒巴坦治疗下呼吸道感染的临床疗效及细菌对该药的耐药性。方法：下呼吸道感染住院病人７３例［男性５３例，女性２０例，年龄（５７ ± ｓ １４） ａ］，应用头孢派酮一舒巴坦 ２． ０ ｇ，加入 ０． ９％氯化钠注射液 １００ ｍｌ。中静脉滴注， ｂｉｄ，疗程（１０ ± ３） ｄ；并对我院临床分离的 ７３８株致病菌进行药敏试验。结果：应用头孢哌酮－舒巴坦治疗的有效率为 ９２％，细菌清除率为 ８４％。头孢哌酮－舒巴坦对临床分离的革兰阴性杆菌的敏感性为 ９４％，对革兰阳性球菌的敏感性为 ８６％。结论：头孢哌酮－舒巴坦治疗下呼吸道感染的临床疗效好，细菌耐药性低，是一种抗菌谱广、杀菌作用强的耐酶抗生素。

AIM: To evaluate the clinical efficacy and safety of cefoperazone/sulbactam in the treatment of lower respiratory tract infections, and its susceptibility rate for bacteria. METHODS: A total of 73 patients with lower respiratory tract infections [M 53, F 20; age (57 ± s 14) a] received cefoperazone/ sulbactam 2. 0 g + 0. 9% sodium chloride injection 100 mL, iv, bid, for (10 ± 3) d. The susceptibility rates of the bacteria to cefoperazone /sulbactam were tested in 738 pathogens isolated from the whole hospital specimens. RESULTS: The overall clinical efficacy rate of cefoperazone/sulbactam was 92%, the bactetialogical clearance rate was 84 %. The susceptibility rates of cefoperazone /sulbactam in 738 isolates were 94% in gram negative bacilli, and 86% in gram positive cocci. CONCLUSION: cefoperazone/sulbactam appears to be an excellent single agent for treatment of bacterial infection of lower respiratory tract infection.